Developer docs
API playgroundTry for free, no card

Search company profiles

Dipharma Francis Srl

Full company profile

uuid000gt6v

Namestring
Dipharma Francis Srl
Legal namestring
Dipharma Francis Srl
Websiteurl
dipharma.it
Company typeenum
Private
Founded yearint
1949
Descriptiontext

Dipharma Francis Srl is a privately held Italian Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) manufacturer headquartered in the Milan metropolitan area (Baranzate), operating as a Società a responsabilità limitata with €8.4M fully paid-up share capital. The company runs two product lines: (i) CDMO-exclusive synthesis services providing custom route development, process optimization, and contract manufacturing for pharmaceutical clients, and (ii) catalogue APIs sold to the generic pharmaceutical market. Underlying capabilities are rooted in process chemistry rather than digital or AI technologies, anchored by 250+ patents, 40+ maintained quality standards, and a self-reported 75+ year operating history.

Short descriptiontext

Dipharma Francis Srl is an Italian privately held CDMO and API manufacturer serving pharmaceutical companies with two product lines: exclusive synthesis (custom process development and contract manufacturing) and catalogue APIs for the generic market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBaranzate, Italy
HQ citystring
Baranzate
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
API manufacturing, CDMO services, exclusive synthesis, generic pharmaceuticals, active pharmaceutical ingredients
Industry4 codes
PRIMARYHLAGABAI
Lyophilization (Freeze-Drying) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical API Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1CDMO Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization services providing exclusive synthesis capabilities to pharmaceutical companies. Revenue derived from long-term manufacturing contracts and custom synthesis projects for drug development and commercial production.

dipharma.com
2Catalogue APIs
TypeOne Time License
Description

Sale of Active Pharmaceutical Ingredients for generic pharmaceutical market. APIs are manufactured and sold to pharmaceutical companies for use in generic drug formulations.

dipharma.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Dipharma Francis Srl is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops, optimizes, and manufactures Active Pharmaceutical Ingredients (APIs) under cGMP conditions for the global pharmaceutical industry. Its commercial offering is split between (1) exclusive synthesis services, providing custom process development and contract manufacturing of complex APIs for branded and generic drug developers, and (2) a catalogue of generic APIs produced at scale for use in finished generic drug formulations.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Dipharma Francis Srl operates as a Global CDMO (Contract Development and Manufacturing Organization) and API manufacturer. The company offers two primary product lines: CDMO Services with Exclusive Synthesis capabilities, and Catalogue APIs for the generic market. With 75+ years of experience, 250+ patents, and 550+ employees, the company provides end-to-end pharmaceutical development and manufacturing services supporting clients through development and manufacturing while they focus on their ultimate goals.

Product and service3 records
1CDMO Services
CategoryCDMO / Pharmaceutical Contract Manufacturing
Description

Contract Development and Manufacturing Organization services providing exclusive synthesis and manufacturing capabilities for pharmaceutical clients from clinical development through commercial supply.

2Exclusive Synthesis
CategoryCDMO / Custom API Synthesis
Description

Custom synthesis services for complex pharmaceutical compounds, providing bespoke process development and small-to-commercial-scale API manufacturing for innovator and generic pharmaceutical clients.

3Catalogue APIs
CategoryActive Pharmaceutical Ingredients (Generic APIs)
Description

Active Pharmaceutical Ingredients (APIs) for the generic market, manufactured in-house at cGMP standards and supplied to generic drug manufacturers worldwide.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

US/EU-based small-molecule API CDMO owned by Permira; comparable in exclusive synthesis and generic API offerings but with greater North American presence than Dipharma.

TypeRegional player
Description

Swiss-based CDMO specializing in peptide APIs; comparable contract manufacturing model though focused on a different molecule class than Dipharma's small-molecule focus.

3Olon S.p.A.
TypeDirect peer
Description

Italian-headquartered API manufacturer offering both generic APIs and custom CDMO services; directly comparable in geography, business model, and product mix to Dipharma's CDMO + catalogue API structure.

TypeDirect peer
Description

Italian CDMO specializing in custom synthesis and API manufacturing for the pharmaceutical industry; competes head-to-head with Dipharma in exclusive synthesis and HPAPI services.

TypeDirect peer
Description

Portuguese-based global CDMO focused on API development and manufacturing, including particle engineering and integrated drug substance/drug product services; directly comparable scale and offering to Dipharma.

TypeDirect peer
Description

European-based CDMO offering API manufacturing and integrated drug product services across multiple modalities; competes with Dipharma in custom synthesis and pharmaceutical contract manufacturing.

TypeDirect peer
Description

French API manufacturer spun off from Sanofi, supplying both branded and generic APIs globally; competes with Dipharma's catalogue API business and offers CDMO services.

TypeBroad incumbent
Description

Swiss-listed CDMO with API and finished drug product manufacturing; larger, publicly-listed, and broader portfolio — overlapping with Dipharma's CDMO/API offering but at greater scale.

TypeBroad incumbent
Description

German pharmaceutical CDMO providing API and drug product services across solid dosage forms, sterile, and semi-solids; overlaps with Dipharma's API and exclusive synthesis services at a broader portfolio level.

10Kalexsyn (Dipharma subsidiary)
TypeEmerging player
Description

US-based custom synthesis CRO acquired by Dipharma in 2018; demonstrates Dipharma's transatlantic expansion and represents the company's own US-facing CDMO capability.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dipharma Francis Srl

Pharmaceutical API Manufacturing (CDMO)dipharma.it

Dipharma Francis Srl is an Italian privately held CDMO and API manufacturer serving pharmaceutical companies with two product lines: exclusive synthesis (custom process development and contract manufacturing) and catalogue APIs for the generic market.

What Dipharma Francis Srl does

Dipharma Francis Srl is a privately held Italian Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) manufacturer headquartered in the Milan metropolitan area (Baranzate), operating as a Società a responsabilità limitata with €8.4M fully paid-up share capital. The company runs two product lines: (i) CDMO-exclusive synthesis services providing custom route development, process optimization, and contract manufacturing for pharmaceutical clients, and (ii) catalogue APIs sold to the generic pharmaceutical market. Underlying capabilities are rooted in process chemistry rather than digital or AI technologies, anchored by 250+ patents, 40+ maintained quality standards, and a self-reported 75+ year operating history.

Dipharma Francis Srl firmographics

Firmographics
Name
Dipharma Francis Srl
Legal name
Dipharma Francis Srl
Website
https://dipharma.it
Company type
Private
Founded year
1949
Operating status
Operating
Headcount range
251–500 employees
Short description
Dipharma Francis Srl is an Italian privately held CDMO and API manufacturer serving pharmaceutical companies with two product lines: exclusive synthesis (custom process development and contract manufacturing) and catalogue APIs for the generic market.
Ownership category
akta.pro rank

Dipharma Francis Srl industry classification

Industry
Product category
Pharmaceutical API Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAI
Lyophilization (Freeze-Drying) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • API manufacturing
  • CDMO services
  • Exclusive synthesis
  • Generic pharmaceuticals
  • Active pharmaceutical ingredients

Where Dipharma Francis Srl is headquartered

Location

Headquarters

HQ city
Baranzate
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

Dipharma Francis Srl business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. CDMO Services: Contract Development and Manufacturing Organization services providing exclusive synthesis capabilities to pharmaceutical companies. Revenue derived from long-term manufacturing contracts and custom synthesis projects for drug development and commercial production.
  2. Catalogue APIs: Sale of Active Pharmaceutical Ingredients for generic pharmaceutical market. APIs are manufactured and sold to pharmaceutical companies for use in generic drug formulations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Dipharma Francis Srl product offering

Product offering

Core offering

Dipharma Francis Srl is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops, optimizes, and manufactures Active Pharmaceutical Ingredients (APIs) under cGMP conditions for the global pharmaceutical industry. Its commercial offering is split between (1) exclusive synthesis services, providing custom process development and contract manufacturing of complex APIs for branded and generic drug developers, and (2) a catalogue of generic APIs produced at scale for use in finished generic drug formulations.

Product overview

Dipharma Francis Srl operates as a Global CDMO (Contract Development and Manufacturing Organization) and API manufacturer. The company offers two primary product lines: CDMO Services with Exclusive Synthesis capabilities, and Catalogue APIs for the generic market. With 75+ years of experience, 250+ patents, and 550+ employees, the company provides end-to-end pharmaceutical development and manufacturing services supporting clients through development and manufacturing while they focus on their ultimate goals.

Differentiator

Problem solved

Functional benefit

Products and services

  • CDMO Services Contract Development and Manufacturing Organization services providing exclusive synthesis and manufacturing capabilities for pharmaceutical clients from clinical development through commercial supply.
  • Exclusive Synthesis Custom synthesis services for complex pharmaceutical compounds, providing bespoke process development and small-to-commercial-scale API manufacturing for innovator and generic pharmaceutical clients.
  • Catalogue APIs Active Pharmaceutical Ingredients (APIs) for the generic market, manufactured in-house at cGMP standards and supplied to generic drug manufacturers worldwide.

Companies that use Dipharma Francis Srl

Customer profile

Segments1 record

Ideal customer profiles2 records

Dipharma Francis Srl technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Dipharma Francis Srl partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Dipharma Francis Srl competitors and assessment

Company assessment

Broad incumbents

  • Cambrex: US/EU-based small-molecule API CDMO owned by Permira; comparable in exclusive synthesis and generic API offerings but with greater North American presence than Dipharma.
  • Siegfried Holding: Swiss-listed CDMO with API and finished drug product manufacturing; larger, publicly-listed, and broader portfolio — overlapping with Dipharma's CDMO/API offering but at greater scale.
  • Aenova Group: German pharmaceutical CDMO providing API and drug product services across solid dosage forms, sterile, and semi-solids; overlaps with Dipharma's API and exclusive synthesis services at a broader portfolio level.

Regional players

  • PolyPeptide Group: Swiss-based CDMO specializing in peptide APIs; comparable contract manufacturing model though focused on a different molecule class than Dipharma's small-molecule focus.

Direct peers

  • Olon S.p.A. Italian-headquartered API manufacturer offering both generic APIs and custom CDMO services; directly comparable in geography, business model, and product mix to Dipharma's CDMO + catalogue API structure.
  • Fabbrica Italiana Sintetici (F.I.S.): Italian CDMO specializing in custom synthesis and API manufacturing for the pharmaceutical industry; competes head-to-head with Dipharma in exclusive synthesis and HPAPI services.
  • Hovione: Portuguese-based global CDMO focused on API development and manufacturing, including particle engineering and integrated drug substance/drug product services; directly comparable scale and offering to Dipharma.
  • CordenPharma: European-based CDMO offering API manufacturing and integrated drug product services across multiple modalities; competes with Dipharma in custom synthesis and pharmaceutical contract manufacturing.
  • EuroAPI: French API manufacturer spun off from Sanofi, supplying both branded and generic APIs globally; competes with Dipharma's catalogue API business and offers CDMO services.

Emerging players

  • Kalexsyn (Dipharma subsidiary): US-based custom synthesis CRO acquired by Dipharma in 2018; demonstrates Dipharma's transatlantic expansion and represents the company's own US-facing CDMO capability.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Dipharma Francis Srl social profiles

Digital presence

Dipharma Francis Srl financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dipharma Francis Srl leadership team

Management profile

Number of profiles

Profiles2 records

Dipharma Francis Srl funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dipharma Francis Srl M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dipharma Francis Srl

What does Dipharma Francis Srl do?

Dipharma Francis Srl is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops, optimizes, and manufactures Active Pharmaceutical Ingredients (APIs) under cGMP conditions for the global pharmaceutical industry. Its commercial offering is split between (1) exclusive synthesis services, providing custom process development and contract manufacturing of complex APIs for branded and generic drug developers, and (2) a catalogue of generic APIs produced at scale for use in finished generic drug formulations.

Is Dipharma Francis Srl a public or private company?

Dipharma Francis Srl is a private company. It is classified as unknown and is currently operating.

When was Dipharma Francis Srl founded?

Dipharma Francis Srl was founded in 1949. It employs 251 to 500 people.

Where is Dipharma Francis Srl based?

Dipharma Francis Srl is headquartered in Baranzate, Italy, in the Europe region.

How does Dipharma Francis Srl make money?

Two revenue lines are on record. CDMO Services are the primary driver. The others are catalogue APIs.

Who are Dipharma Francis Srl's main competitors?

Broad incumbents on record are Cambrex, Siegfried Holding and Aenova Group. PolyPeptide Group is listed as a regional player. Direct peers are Olon S.p.A., Fabbrica Italiana Sintetici (F.I.S.), Hovione, CordenPharma and EuroAPI. Kalexsyn (Dipharma subsidiary) is listed as an emerging player.

Does Dipharma Francis Srl have an API?

No public API is recorded for Dipharma Francis Srl.

What industry is Dipharma Francis Srl in?

Dipharma Francis Srl's product category is Pharmaceutical API Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAI, Lyophilization (Freeze-Drying) CDMO, with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals